In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120

Virology

Volumn 372, Issue 2, 2008, Pages 409-420

  Visciano, Maria Luisa ^a   Tuen, Michael ^a   Gorny, Miroslaw K ^a   Hioe, Catarina E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; HIV; HIV envelope gp120; Immune complex

Indexed keywords

GLYCOPROTEIN 120 CD4 MONOCLONAL ANTIBODY COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PEPTIDE; UNCLASSIFIED DRUG; V3 PEPTIDE; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD4; BINDING SITES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 39749120498     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.10.044     Document Type: Article

References (54)

1. Alber D.G., Killington R.A., and Stokes A. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Vaccine 19 7-8 (2000) 895-901
2. Bandres J.C., Wang Q.F., O'Leary J., Baleaux F., Amara A., Hoxie J.A., Zolla-Pazner S., and Gorny M.K. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J. Virol. 72 3 (1998) 2500-2504
3. Bouige P., Iscaki S., Cosson A., and Pillot J. Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. FEMS Immunol. Med. Microbiol. 13 1 (1996) 71-79
4. Brady L.J., van Tilburg M.L., Alford C.E., and McArthur W.P. Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans. Infect. Immun. 68 4 (2000) 1796-1805
5. Chien Jr. P.C., Cohen S., Kleeberger C., Giorgi J., Phair J., Zolla-Pazner S., and Hioe C.E. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J. Infect. Dis. 186 2 (2002) 205-213
6. Chien Jr. P.C., Chen D., Chen P.D., Tuen M., Cohen S., Migueles S.A., Connors M., Rosenberg E., Malhotra U., Gonzalez C., and Hioe C.E. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation. J. Infect. Dis. 189 5 (2004) 852-861
7. Chien Jr. P.C., Cohen S., Tuen M., Arthos J., Chen P.D., Patel S., and Hioe C.E. Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J. Virol. 78 14 (2004) 7645-7652
8. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan Jr. G.V., and Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 1 (2007) 79-90
9. Dawe D.L., Myers W.L., and Segre D. Enhancement of the immune response in rabbits by administration of immunoglobulin-G. Immunology 18 6 (1970) 897-907
10. Denisova G., Stern B., Raviv D., Zwickel J., Smorodinsky N.I., and Gershoni J.M. Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res. Hum. Retrovir. 12 10 (1996) 901-909
11. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., DeVico A., and Pal R. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 99 18 (2002) 11842-11847
12. Gaspal F.M., McConnell F.M., Kim M.Y., Gray D., Kosco-Vilbois M.H., Raykundalia C.R., Botto M., and Lane P.J. The generation of thymus-independent germinal centers depends on CD40 but not on CD154, the T cell-derived CD40-ligand. Eur. J. Immunol. 36 7 (2006) 1665-1673
13. Gigler A., Dorsch S., Hemauer A., Williams C., Kim S., Young N.S., Zolla-Pazner S., Wolf H., Gorny M.K., and Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73 3 (1999) 1974-1979
14. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., and Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66 12 (1992) 7538-7542
15. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., and Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150 2 (1993) 635-643
16. Haigwood N.L., Nara P.L., Brooks E., Van Nest G.A., Ott G., Higgins K.W., Dunlop N., Scandella C.J., Eichberg J.W., and Steimer K.S. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66 1 (1992) 172-182
17. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 5730 (2005) 1906-1908
18. He Y., D'Agostino P., and Pinter A. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 21 27-30 (2003) 4421-4429
19. Heyman B. The immune complex: possible ways of regulating the antibody response. Immunol. Today 11 9 (1990) 310-313
20. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18 (2000) 709-737
21. Hioe C.E., Xu S., Chigurupati P., Burda S., Williams C., Gorny M.K., and Zolla-Pazner S. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9 9 (1997) 1281-1290
22. Hochleitner E.O., Gorny M.K., Zolla-Pazner S., and Tomer K.B. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A. J. Immunol. 164 8 (2000) 4156-4161
23. Ivan J., Velhner M., Ursu K., German P., Mato T., Dren C.N., and Meszaros J. Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can. J. Vet. Res. 69 2 (2005) 135-142
24. Jeffs S.A., Gorny M.K., Williams C., Revesz K., Volsky B., Burda S., Wang X.H., Bandres J., Zolla-Pazner S., and Holmes H. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol. Lett. 79 3 (2001) 209-213
25. Jemmerson R., and Paterson Y. Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science 232 4753 (1986) 1001-1004
26. Kang C.Y., Hariharan K., Nara P.L., Sodroski J., and Moore J.P. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J. Virol. 68 9 (1994) 5854-5862
27. Karwowska S., Gorny M.K., Buchbinder A., Gianakakos V., Williams C., Fuerst T., and Zolla-Pazner S. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retrovir. 8 6 (1992) 1099-1106
28. Kessler II J.A., McKenna P.M., Emini E.A., Chan C.P., Patel M.D., Gupta S.K., Mark III G.E., Barbas III C.F., Burton D.R., and Conley A.J. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retrovir. 13 7 (1997) 575-582
29. Kumar R. Virus enhancement following infection with antibody-coated infectious bursal disease virus (IBDV) in chickens. Indian J. Exp. Biol. 39 12 (2001) 1314-1317
30. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., and Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 6916 (2002) 678-682
31. Liao H.X., Alam S.M., Mascola J.R., Robinson J., Ma B., Montefiori D.C., Rhein M., Sutherland L.L., Scearce R., and Haynes B.F. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J. Virol. 78 10 (2004) 5270-5278
32. Mbah H.A., Burda S., Gorny M.K., Williams C., Revesz K., Zolla-Pazner S., and Nyambi P.N. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J. Virol. 75 16 (2001) 7785-7788
33. McCluskie M.J., Wen Y.M., Di Q., and Davis H.L. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 11 4 (1998) 245-252
34. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70 3 (1996) 1863-1872
35. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., and Ho D.D. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68 12 (1994) 8350-8364
36. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nadas A., and Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74 15 (2000) 7096-7107
37. Oli M.W., Rhodin N., McArthur W.P., and Brady L.J. Redirecting the humoral immune response against Streptococcus mutans antigen P1 with monoclonal antibodies. Infect. Immun. 72 12 (2004) 6951-6960
38. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., and Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77 1 (2003) 642-658
39. Pinter A., Honnen W.J., and Tilley S.A. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J. Virol. 67 9 (1993) 5692-5697
40. Posner M.R., Hideshima T., Cannon T., Mukherjee M., Mayer K.H., and Byrn R.A. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146 12 (1991) 4325-4332
41. Raja A., Venturi M., Kwong P., and Sodroski J. CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J. Virol. 77 1 (2003) 713-718
42. Roic B., Cajavec S., Ergotic N., Lipej Z., Madic J., Lojkic M., and Pokric B. Immune complex-based vaccine for pig protection against parvovirus. J. Vet. Med. B. Infect. Dis. Vet. Public Health 53 1 (2006) 17-23
43. Sattentau Q.J., and Moore J.P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174 2 (1991) 407-415
44. Sattentau Q.J., Moore J.P., Vignaux F., Traincard F., and Poignard P. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67 12 (1993) 7383-7393
45. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., and Vitetta E.S. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334 6179 (1988) 255-258
46. Thali M., Furman C., Ho D.D., Robinson J., Tilley S., Pinter A., and Sodroski J. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66 9 (1992) 5635-5641
47. Tuen M., Visciano M.L., Chien Jr. P.C., Cohen S., Chen P.D., Robinson J., He Y., Pinter A., Gorny M.K., and Hioe C.E. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur. J. Immunol. 35 9 (2005) 2541-2551
48. Wen Y.M., Qu D., and Zhou S.H. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int. Rev. Immunol. 18 3 (1999) 251-258
49. Wernersson S., Kleinau S., and Heyman B. Immune complex-mediated enhancement of antibody responses without induction of delayed-type hypersensitivity. Scand. J. Immunol. 52 6 (2000) 563-569
50. Wiersma E.J., Coulie P.G., and Heyman B. Dual immunoregulatory effects of monoclonal IgG-antibodies: suppression and enhancement of the antibody response. Scand. J. Immunol. 29 4 (1989) 439-448
51. Wilkinson R.A., Piscitelli C., Teintze M., Cavacini L.A., Posner M.R., and Lawrence C.M. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J. Virol. 79 20 (2005) 13060-13069
52. Xiang S.H., Kwong P.D., Gupta R., Rizzuto C.D., Casper D.J., Wyatt R., Wang L., Hendrickson W.A., Doyle M.L., and Sodroski J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76 19 (2002) 9888-9899
53. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., and Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 7129 (2007) 732-737
54. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum. Antib. 14 3-4 (2005) 69-72